As of 2026-08-28, MapLight Therapeutics, Inc. (MPLT) trades at $12.54 against an EvidInvest fair-value range of $52.53–$579 (base estimate $104), built from 3 independent valuation methods on filed financial statements. The market price is 88% below the base estimate, so the models read the stock as undervalued. Research, not investment advice.
Download the full MPLT valuation report (PDF) — free
DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.
PEG Ratio is not meaningful: EPS growth rate unavailable
Interpretation
PEG = P/E ÷ Annual EPS Growth Rate (%). Peter Lynch's growth-adjusted value metric.
EV/EBITDA is not meaningful: EBITDA data unavailable
Interpretation
EV/EBITDA = Enterprise Value ÷ EBITDA. Capital-structure neutral — preferred by professional investors.
P/S Ratio is not meaningful: Revenue data unavailable
Interpretation
P/S = Market Cap ÷ Revenue. Useful for growth/unprofitable companies. SaaS/high-growth norms higher.
Interpretation
P/B = Price ÷ Book Value per Share. Essential for banks, REITs, and asset-heavy companies.
Graham Number is not meaningful: Negative or zero EPS — Graham Number not meaningful
Interpretation
√(22.5 × EPS × Book Value/Share) — Benjamin Graham's intrinsic value estimate.
EPV not meaningful: Negative operating earnings
Greenwald EPV assumes zero future growth — this is the floor value of the business as a going concern.